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Abstract
The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene plays a critical role in folate 
metabolism. Studies on the association between MTHFR polymorphisms and length changes in 
short tandem repeat DNA sequences [microsatellite instability (MSI)] are inconsistent. Using data 
from colon cancer cases (n = 503) enrolled as part of an existing population-based case-control 
study, we investigated the association between MTHFR 677 and MTHFR 1298 polymorphisms 
and MSI. We also examined whether the association was modified by folate intake. Participants 
were case subjects enrolled as part of the North Carolina Colon Cancer Study. Consenting cases 
provided information about lifestyle and diet during in-home interviews as well as blood 
specimens and permission to obtain tumor blocks. DNA from normal and tumor tissue sections 
was used to determine microsatellite status (MSI). Tumors were classified as MSI if two or more 
microsatellite markers (BAT25, BAT26, D5S346, D2S123, and D17S250) had changes in the 
number of DNA sequence repeats compared with matched nontumor tissue. Tumors with one 
positive marker (MSI-low) or no positive markers (microsatellite stable) were grouped together as 
non-MSI tumors (microsatellite stable). MTHFR 677 and MTHFR 1298 genotypes were 
determined by real-time PCR using the 5′ exonuclease (Taqman) assay. Logistic regression was 
used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). MSI was more common 
in proximal tumors (OR, 3.8; 95% CI, 1.7–8.4) and in current smokers (OR, 4.0; 95% CI, 1.6–
9.7). Compared with MTHFR 677 CC referent, MTHFR 677 CT/TT genotype was inversely 
associated with MSI among White cases (OR, 0.36; 95% CI, 0.16–0.81) but not significant among 
African Americans. Although not statistically significant, a similar inverse association was 
observed between MTHFR 677 CT/TT genotype and MSI among the entire case subjects (OR, 
0.54; 95% CI, 0.26–1.10). Among those with adequate folate intake (>400 μg total folate), we 
found strong inverse associations between combined MTHFR genotypes and MSI (677 CC + 1298 
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AC/CC, OR, 0.09; 95% CI, 0.01–0.59; 677 CT/TT + 1298 AA, OR, 0.13; 95% CI, 0.02–0.85) 
compared with the combined wild-type genotypes (677 CC + 1298 AA). This protective effect 
was not evident among those with low folate (<400 μg total folate) intake. Our results suggest that 
MTHFR variant genotypes are associated with reduced risk of MSI tumors under conditions of 
adequate folate intake, although the data are imprecise due to small numbers. These results 
indicate that the relationship between MTHFR genotypes and MSI is influenced by folate status.
Introduction
Colon cancer, a common cancer in the United States and other developed countries, is 
thought to have a strong environmental component. Among environmental exposures, diet 
has received a great deal of attention. There are at least three pathways to colon cancer: 
chromosomal instability, microsatellite instability (MSI), and CpG island methylator 
phenotype. Some sporadic colon cancers are associated with chromosomal instability, which 
involves allelic loss of tumor suppressor genes, such as p53 or APC. Microsatellites are 
short tandem repeat DNA sequences. The change in length of these tandem repeats is termed 
MSI and is often associated with defects in DNA repair genes (1, 2). MSI is associated with 
10% to 15% of sporadic colorectal carcinomas (3). Colon tumors harboring MSI more 
frequently present with proximal location, large tumor size, decreased likelihood of 
metastasis, less advanced stage at diagnosis, and better prognosis compared with 
microsatellite-stable (MSS) colon cancers (4, 5). Some colon cancers exhibit aberrant DNA 
methylation or CpG island methylator phenotype, which involves inactivation or silencing 
of genes by hypermethylation of promoter cytosine-guanosine (CpG) residues. Interestingly, 
MSI arises through aberrant methylation of the hMLH1 promoter in sporadic colon cancers 
(6, 7).
Folate is ingested through diet (e.g., dark green vegetables, eggs, fish, and wheat) or 
supplements. Evidence from epidemiologic studies suggest that adequate folate intake is 
associated with decreased risk of colorectal cancer (8–11), although not all studies support 
this association (12, 13). Folate is integral in the processes of both DNA synthesis and DNA 
methylation. The 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme plays an 
important role in folate metabolism and determines the balance between the different forms 
of folate for DNA synthesis and DNA methylation (14). MTHFR catalyzes the reduction of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a substrate for the conversion 
of homocysteine to methionine. The latter is a precursor to S-adenosylmethionine, which is 
an important methyl donor for DNA methylation. In addition, 5,10-
methylenetetrahydrofolate, a substrate of MTHFR, is also required for thymidylate and 
purine synthesis. However, low folate may lead to uracil misincorporation into DNA 
chromosomal breaks and increase the potential for premutagenic lesions (15, 16). Folate 
deficiency has also been linked to increased chromosomal aberrations in mammalian cells 
during mitosis (17). Altered folate metabolism lead to shifts in the balance between 
availability of 5-methyltetrahydrofolate for methylation reactions and 5,10-
methylenetetrahydrofolate for DNA synthesis and repair (18, 19) may influence colorectal 
cancer risk.
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Not surprisingly, polymorphisms in genes related to folate metabolism, specifically MTHFR, 
are thought to play a role in carcinogenesis of the large bowel. Two polymorphisms in the 
MTHFR gene that affect the efficiency of folate metabolism have been described (20–22). 
The MTHFR 677 C>T transition in exon 4 and MTHFR 1298 A>C transversion in exon 7 
are associated with reduced enzyme activity resulting in slower folate metabolism. The 
MTHFR 677 TT genotype results in 30% enzyme activity in vitro compared with the CC 
wild-type (23), whereas the MTHFR 1298 CC genotype has been found to have 60% of the 
AA wild-type enzyme activity in vitro (22, 24). We have shown previously a significantly 
reduced risk of colon cancer among Whites with the MTHFR 1298 CC variant genotype 
(20). Other studies also reported reduced risk of colorectal cancer among individuals 
homozygous for MTHFR 677 TT genotype with high folate intake (10, 25, 26). Studies on 
colorectal adenomas, colorectal cancer precursors, suggest positive association between 
MTHFR 677 TT genotype and adenoma risk, under inadequate folate status (27, 28). These 
observations indicate that the effect of MTHFR polymorphisms on colon adenoma and 
cancer risk is likely modifiable by folate status. MTHFR 677 T or MTHFR 1298 C 
polymorphisms combined with inadequate folate intake could lead to aberrant DNA 
methylation. MTHFR polymorphisms associated with reduced enzyme activity limit the 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the form of folate 
required for DNA methylation. Interestingly, MTHFR 677 TT genotype has been associated 
with reduced DNA methylation under low folate conditions (29, 30). On the other hand, 
MTHFR polymorphisms that are associated with reduced enzyme activity enhance the 
accumulation of 5,10-methylenetetrahydrofolate (31) for DNA synthesis by providing more 
nonmethylated folate for nucleotide synthesis and DNA repair (32). Low folate is associated 
with increased uracil misincorporation during DNA synthesis (33) and increased frequency 
of DNA strand breaks (15).
No studies have examined the relationship among MTHFR polymorphisms, MSI, and folate 
status in relation to colon cancer. The findings from the few studies that examined MSI and 
MTHFR polymorphisms are not consistent. A recent study reported a modest but not 
significant inverse association between MTHFR TT genotype and MSI (34), whereas 
another study observed a higher frequency of MTHFR TT genotype among colorectal cancer 
cases with MSI tumors (35). A third study found no association between MTHFR TT 
genotypes and MSI (36). In this study, we hypothesized that in colon cancer subjects 
MTHFR 677 T and MTHFR 1298 C polymorphisms would be associated with MSI and that 
the association between MTHFR and MSI would be modified by folate intake. We also 
hypothesized that there would be differences by race given the disparities in incidence and 
mortality and the distribution of MTHFR gene polymorphisms by race.
Materials and Methods
Study Design
Participants in this study were colon cancer cases enrolled as part of a separate study, the 
North Carolina Colon Cancer Study, a population-based case-control study of colon cancer 
in 33 counties of central and eastern North Carolina. Details about the North Carolina Colon 
Cancer Study have been described previously (20). Colon cancer cases were identified 
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through the rapid ascertainment system of the North Carolina Central Cancer Registry. All 
African Americans and a sample of Whites were recruited between October 1, 1996 and 
September 1, 2000. Colon cancer patients ages between 40 and 80 years residing in the 33-
county area with confirmed invasive adenocarcinoma of the colon were considered eligible. 
A total of 676 interviews were completed among colon cancer cases in North Carolina 
Colon Cancer Study. The cooperation rate among cases [interviewed / (interviewed + 
refused)] was 84%. MSI data were collected on 503 cases. Of these, 486 had data on 
MTHFR genotype or folate intake and these were the people included in the analyses. Tissue 
specimens were prospectively collected under institutional review board approval as part of 
the North Carolina Colon Cancer Study. Formalin-fixed, paraffin-embedded colon blocks 
containing tumor or normal (tumor-free) tissue were identified from pathology reports and 
blocks were requested from participating hospitals. The study pathologist evaluated a 
reference slide from each block that was stained with H&E to confirm the initial diagnosis 
and also to identify areas of normal and tumor tissues for microdissection on additional 
serial tissue sections.
Trained nurse interviewers conducted interviews in the participants’ homes. The interviews 
covered lifestyle and dietary habits, physical activity, smoking and alcohol use, family 
history of colon cancer, personal attributes, and non-steroidal anti-inflammatory drug 
(NSAID) usage. Dietary information (frequency and serving size) was collected using a 
modified version of the semiquantitative Block food frequency questionnaire developed at 
the National Cancer Institute (NCI; ref. 37). The food questionnaire was modified by adding 
29 food items consumed in North Carolina (38). Participants were asked to estimate their 
usual frequency of intake of various foods and portion sizes for the year before diagnosis. 
The 1-year period was selected to account for seasonal variations in dietary intake. We used 
the nutrients database program provided by NCI to compute estimates of usual intake for a 
variety of nutrients, including calcium and folate intake, for the year before diagnosis. In 
addition, use of NSAIDs during the previous 5 years was assessed. The University of North 
Carolina Medical School Institutional Review Board approved the study protocol.
Blood Collection
Blood was collected following the interview after receiving written consent from the 
participant. The blood specimens were kept at 4°C to 21°C for up to 48 hours during transit 
to the laboratory. DNA samples were extracted from the buffy coats using the Puregene 
DNA isolation kit following the manufacturer’s recommendations (Gentra Systems, Inc., 
Minneapolis, MN).
MSI Status
DNA was extracted from normal and tumor tissue sections from formalin-fixed, paraffin-
embedded tissue sections. A H&E-stained section was used as a guide for microdissection. 
Genomic DNA was extracted from the tissue by deparaffinization in xylene, purified with 
absolute alcohol, and pelleted at maximum speed in a microcentrifuge. The pellets were 
dried in a DNA SpeedVac (Savant, Inc., Farmingdale, NY) and resuspended in 15 μL 
Genereleaser (BioVentures, Inc., Murfeesboro, TN) according to the manufacturer’s 
protocol. The resuspended DNA was then incubated overnight at 55°C, with 200 mg/mL 
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proteinase K (Sigma, St. Louis, MO). This product was then used directly in the PCR 
reactions.
To determine MSI in the pathologic specimens, a reference panel of five NCI-recommended 
microsatellite markers (BAT25, BAT26, D5S346, D2S123, and D17S250) were used (39). 
The reaction to end-label one primer from each pair contained the primers, kinase buffer, T4 
polynucleotide kinase, and 32P/33P. The PCR reaction contained 0.125 pmol of each primer 
in the pair, 0.25 units Taq DNA polymerase, 40 mmol/L deoxynucleotide triphosphate mix, 
and 1.5 to 2.0 mmol/L MgCl2. The PCR products were denatured in 95% formamide and 
used for electrophoresis on a 6% polyacrylamide/7.5 mol/L urea gel. Mutations, identified 
by changes in the electrophoretic mobility of the PCR products, were analyzed by 
autoradiography. Alleles in the tumor DNA were compared with nontumor DNA taken from 
the same specimen. The sample was defined as having high MSI if two or more of the five 
markers contained novel alleles in the tumor compared with matched nontumor tissue and as 
MSS if none of the markers had novel alleles. Specimens with one of five positive markers 
were defined as MSI-low and combined with the MSS group as non-MSI tumors (MSS). 
Among the 486 subjects with MSI, folate, and MTHFR genotype data, the frequencies of 
MSI and MSS were 10.1% and 89.9%, respectively.
Genotyping
Genotyping was done as reported previously (20) using the RFLP assay and the 5′ 
exonuclease (Taqman, Applied Biosystems, Foster City, CA) assays. Primers for the RFLP 
assay were MTHFR 677 forward 5′-AGGACGGTGC-GGTGAGAGTG-3′and reverse 5′-
TGAAGGAGAAGGTGTCT-GCGG-3′ and MTHFR 1298 forward 5′-CTTTGGGGAGCT-
GAAGGACTACTAC-3′ and reverse 5′-CACTTTGTGAC-CATTCCGGTTTG-3′. The 5′ 
exonuclease assay primer and probe sequences are as follows: MTHFR 677 forward 5′-
AGGCT-GACCTGAAGCACTTGAA-3′ and reverse 5′-CTCAAA-
GAAAGCTGCGTGATGA-3′; probes end-labeled with the quencher and reporter dyes: 
VIC-TGTCTGCGGG AGCC-CGATTTCA for the common allele and FAM-
AGGTGTCTG-CGGGAGTCGATTTCA for the variant allele; MTHFR 1298 forward 5′-
AAGGAGGAGCTGCTGAAGATGT-3′and reverse 5′-TGTGACCATTCCGGTTTGG-3′; 
probes: VIC-AAGA-CACTTTCTTCACTG (A allele) and FAM-AGACACTTGCTT-
TCACT (C allele). At least four negative template controls as well as five positive controls 
for each allele were included with every assay. A random 10% repeat of samples was done 
using both methods, with 100% agreement.
Statistical Analysis
The response of interest was MSI. MSI was dichotomized into MSI versus non-MSS (MSI-
low + MSS). The main exposures of interest in this study were folate intake and MTHFR 
genotype. Three different measures of folate intake were evaluated: total folate, dietary 
folate, and supplemental folate. The Block-NCI program was used to determine the amounts 
of dietary and supplemental folate intake. Total folate was the summation of the reported 
microgram amounts of supplemental folate and dietary folate intake. Dichotomous variables 
were created from the continuous data for both total folate and dietary folate. For total 
folate, 400 μg was chosen as the cut point because it is the current recommended daily 
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allowance and it was used in previous studies (20). For dietary folate, we used the mean 
intake of 275 μg. The odds ratios (OR) did not differ when we used the median intake of 
dietary folate (257 μg) as the cut point (data not shown). Supplemental folate was collapsed 
into either yes, supplement taken, or no, supplement not taken.
There are three genotypes for each MTHFR locus: a homozygous wild-type or common 
allele, a homozygous variant allele, and a heterozygote, which has one copy of each allele. 
For both genotypes, heterozygotes and variant alleles were collapsed into one category to 
increase precision, thereby creating a dichotomous variable for each locus.
Covariates tested were total calcium intake (quartiles), multivitamin use [use regularly (>3 
days a week), use occasionally (>1 day a month but <3 days a week), or do not use], family 
history (at least one first-degree relative with colorectal cancer: yes/no), alcohol use 
(nonuser, lower half of consumers, or upper half of consumers), smoking (never, former, or 
current), NSAID use during the past 5 years before diagnosis [never, occasionally (>1 day a 
month but <3 days a week), or frequently (≥3 days a week)], stage at time of diagnosis 
(local, regional, or distal), and tumor location (proximal or distal).
Proc Logistic (SAS 8.2, SAS Institute, Cary, NC) was used to calculate ORs and 95% 
confidence intervals (95% CI). Covariates were included if they resulted in at least a 10% 
difference between ORs for the main exposure of interest in the crude and adjusted models. 
Ps were considered statistically significant at the <0.05 level. Interaction terms were created 
for the combinations for MTHFR and folate.
For all interaction models, race, sex, and age were included in the adjusted model. To test 
for multiplicative interaction, the interaction term was added to the model and evaluated 
using the likelihood ratio test. To test for additive interaction, the ORs and their variances 
from the model with the interaction term were used to find an interaction contrast ratio and 
its corresponding 95% CI and from that a P was generated test the null hypothesis that the 
interaction contrast ratio is equal to 0 (no interaction).
Results
Table 1 provides the ORs with 95% CIs for the association between MSI and general 
characteristics among colon cancer cases. Age, White race, proximal location of tumor, high 
alcohol intake, and both former and current smoking were significantly associated with the 
likelihood of having MSI. Frequent use of NSAIDs versus no use over the past 5 years was 
associated with lower likelihood of MSI. Gender, family history, stage at the time of 
diagnosis, alcohol use, occasional NSAID use, calcium intake, and vitamin/supplement use 
were not significantly associated with MSI.
Table 2 provides the ORs for the association between MSI and total, dietary, and 
supplemental folate intake. There were no associations between MSI and the various forms 
of folate. We examined the relationship between MTHFR polymorphisms (MTHFR 677 
C>T and MTHFR 1298 A>C) and MSI among the entire study subjects and by race. 
However, we had limited power due to small numbers. To increase precision, we combined 
the MTHFR heterozygotes and homozygous variant genotypes (677 CT + TT; 1298 AC + 
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CC) for each polymorphism separately. Among the entire case subjects, there was a 
nonsignificant inverse association between MTHFR CT/TT genotype and MSI (677 CT/TT, 
OR, 0.54; 95% CI, 0.26–1.10 versus 677 CC wild-type referent). Among White subjects, 
those with MTHFR CT/TT genotype were significantly less likely to have MSI (OR, 0.36; 
95% CI, 0.16–0.81) compared with the MTHFR 677 CC wild-type referent. Among African 
Americans, there was no significant association between MTHFR CT/TT genotype and MSI. 
These data should be interpreted with caution because of unstable estimates due to small 
numbers. There was no association between MTHFR 1298 AC/CC genotype and MSI 
among entire subjects and in stratified analysis by race. For MTHFR 677 and MTHFR 1298 
haplotypes (677 CT/TT + 1298 AC/CC compared with wild-type 677 CC + 1298 AA) and 
MSI, the results were suggestive of inverse relation to MSI, but the results were not 
significant (OR, 0.51; 95% CI, 0.13–1.80).
Results for the relationship among MTHFR genotypes, total, dietary, or supplemental folate, 
and MSI are found in Table 3. Variables that resulted in at least a 10% difference between 
ORs for the main exposure of interest in the crude and adjusted models (age, race, tumor 
location, smoking status, total calcium intake, and vitamin/mineral supplement use) were 
included in the models. In all combinations, the MTHFR common wild-type genotypes 677 
CC or 1298 AA and high total, dietary, or supplemental folate were used as the reference. 
Compared with the reference, those with MTHFR 1298 AC/CC genotype and adequate total 
folate (>400 μg) were less likely to have MSI (OR, 0.18; 95% CI, 0.04–0.73). Similarly, 
those with MTHFR 1298 AC/CC genotype and supplemental folate also showed significant 
inverse association to MSI (OR, 0.10; 95% CI, 0.01–0.81). Compared with the reference 
(677 CC + >275 μg dietary folate), subjects with MTHFR 677 CT/TT genotype and dietary 
folate intake >275 μg were less likely to have MSI (OR, 0.11; 95% CI, 0.52), but there was 
no association between MTHFR 1298 AC/CC genotype/high dietary folate and MSI (Table 
3).
ORs for combined MTHFR genotypes and MSI among those with adequate folate are 
presented in Table 4A. Among those with high total folate (>400 μg), MTHFR variant 
genotypes were significantly associated with reduced risk of MSI, although some of the cell 
sizes are small. Among those with low folate intake, the results suggest a slight positive 
association between combined MTHFR variants and MSI, although not significant (Table 
4B).
Interaction terms were created for the combinations for MTHFR and folate. For all 
interaction models, race, sex, and age were included in the adjusted model. There was 
evidence for multiplicative (P = 0.01) and additive (P = 0.001) interaction between MTHFR 
1298 genotype and total folate intake. The same was true for MTHFR 1298 AC/CC and 
supplemental folate (additive P = 0.001, multiplicative P = 0.02) and MTHFR 677 CT/TT 
and dietary folate (additive P = 0.01, multiplicative P = 0.01). None of the remaining 
interaction models, whether additive or multiplicative, resulted in a statistically significant 
result. We were unable to stratify the interactions by race due to low numbers in the African 
American category, which made the models unreliable.
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In this study, we investigated the association of two MTHFR polymorphisms, codons 677 
C>T and 1298 A>C, folate intake, and MSI status among colon cancer cases. We 
hypothesized that MTHFR polymorphisms that are linked with reduced MTHFR enzyme 
activity would be associated with greater risk of colon tumors exhibiting MSI and that the 
association would be modified by folate status. We found that the relationship between 
MTHFR polymorphisms and MSI was influenced by folate status. Among subjects with 
adequate folate (>400 μg), the combined MTHFR 677 and MTHFR 1298 variant genotypes 
were associated with reduced risk of MSI tumors. This protective effect was not evident 
under low folate conditions. We examined the relationship between MTHFR genotypes and 
MSI among all case subjects and in stratified analysis by race. We observed inverse 
association between MTHFR 677 CT/TT genotype and MSI for all case subjects, but the 
association was only significant among Whites. The relationship between MTHFR 1298 
AC/CC genotype and MSI was close to the null.
Several studies but not all have shown reduction in colorectal cancer risk among individuals 
homozygous for MTHFR 677 TT under conditions of adequate folate intake (10, 25, 26, 40). 
These observations suggest that the protective effects of MTHFR variant genotypes on colon 
cancer risk may be modified by interactions with folate intake. In this study, combined 
MTHFR variant genotypes (677 CT/TT + 1298 AA; 677 CC + 1298 AC/CC; Table 4) were 
inversely related to the risk of MSI tumors in the presence of adequate folate intake. A 
possible explanation for this finding may relate to more efficient metabolism when folate 
intake is adequate. For instance, it is known that MTHFR variant genotypes with lower 
enzyme activity favor increased availability of the nonmethylated form of folate 5,10-
methylenetetrahydrofolate for DNA synthesis and decreased levels of 5-
methyltetrahydrofolate, the form of folate required for DNA methylation. However, when 
there is adequate supply of folate, although MTHFR activity is low, presumably, enough 
folate is being converted to 5-methyl-tetrahydrofolate for DNA methylation while at the 
same time shunting 5,10-methylenetetrahydrofolate toward DNA synthesis for the 
conversion of uracil to thymidine. However, MTHFR 677 TT genotype in combination with 
low folate disrupts DNA methylation and may contribute to carcinogenesis (29). Indeed, 
emerging evidence implicates aberrant DNA methylation as an important component in the 
pathways leading to colorectal cancer. Aberrant DNA methylation, particularly in tumor 
suppressor and DNA mismatch repair genes, presumably acts through global 
hypomethylation or hypermethylation of specific CpG islands to promote gene inactivation. 
Hypermethylation of the hMLH1 promoter has been observed in most sporadic colorectal 
cancer with MSI (41) particularly when there is no evidence of mutations in DNA MMR 
genes (35, 42). However, we did not evaluate DNA methylation and mutations in MMR 
genes in this study.
Contrary to our predictions, we found an inverse relationship between MTHFR variant 
genotypes and MSI. MTHFR 677 and MTHFR 1298 variants are linked with reduced 
enzyme activity. The MTHFR 677 TT genotype is associated with 30% reduced enzyme 
activity (21) compared with CC wild-type; therefore, our findings may be related to lower 
MTHFR enzyme activity. The increased availability of 5,10-methylene-tetrahydrofolate 
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associated with reduced MTHFR activity favors DNA synthesis and repair, thereby resulting 
in less uracil misincorporation and decreased DNA strand breaks (15) and presumably 
leading to more MSS tumors. The MTHFR 1298 C variant affects enzyme activity to a lesser 
degree than MTHFR 677 T variant (22). We did not observe a relationship between MTHFR 
1298 C variant and MSI. This finding could be related to higher MTHFR 1298 enzyme 
activity. Although the two MTHFR variants are in linkage disequilibrium (43), we found no 
evidence for linkage disequilibrium between the two MTHFR polymorphisms in our study 
population. A recent study reported that the modest reduction in colorectal cancer risk 
associated with MTHFR 1298 A>C may be independent of the MTHFR 677 C>T (43).
Very few studies have examined the relationship between MTHFR polymorphisms and 
MSI. Toffoli et al. (34) observed a borderline inverse association between MTHFR 677 TT 
genotype and MSI but found no significant association between MTHFR 1298 CC genotype 
and MSI status. Our findings are similar but stronger than the results of the study by Toffoli 
et al. but conflict with two other studies. Shannon et al. (35), observed that MSI tumors were 
more common among older colorectal cancer cases with MTHFR TT genotype compared 
with those with MSS tumors, whereas Plaschke et al. (36) reported no significant 
associations between MTHFR genotypes and MSI. The reasons for these conflicting 
observations are not entirely clear. Our results differ from these two studies and may reflect 
differences in methodologies. For example, Shannon et al. (35) assessed MSI status using 
only one microsatellite marker (BAT26), whereas we used the panel of five microsatellite 
markers recommended by NCI. Differences in the classification of MSI resulting from 
testing a varying number of loci at different sites may contribute to conflicting reports in the 
literature (44). In our analysis, we used the common MTHFR 677 wild-type genotypes (CC) 
as referent and the heterozygote and variant genotypes (CT + TT) were combined to 
increase precision. Shannon et al. (35) and Plaschke et al. (36) combined the common 
MTHFR 677 wild-type and heterozygote genotypes (CT) as the referent group.
Not many studies have examined the relationship between dietary factors, such as folate, and 
colorectal tumors exhibiting MSI. Interestingly, we found no associations between MSI and 
folate intake (total, dietary, and supplemental). Our results agree with the observations of 
Slattery et al. (45), who evaluated the relationship between dietary intake of various 
nutrients and foods in relation to MSI and reported no associations between most dietary 
factors and MSI, except for alcohol consumption. The inverse associations that we observed 
between MTHFR haplotypes and MSI would suggest that, under conditions of adequate 
folate, the DNA synthesis and repair process is favored which likely leads to MSS tumors.
The strengths of this study include the effort to thoroughly collect pathologic specimens for 
MSI analysis, nutritional data, recruitment of cases from a region that contained both rural 
and urban areas, and the deliberate recruitment of both African Americans and Whites. To 
our knowledge, stratification by race for MSI studies has not been addressed before. The 
weaknesses of our study include the following issues. We estimated folate intake from the 
Block-NCI food frequency questionnaire. Estimation of nutrient intake from self-reported 
dietary information collected after diagnosis of disease in cases is subject to recall bias. In 
addition, we assumed in our study that folate supplement users took daily tablet containing 
400 μg, which could have overestimated folate intake in some people. However, the results 
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did not differ when we assumed lower values of folate for supplement users (data not 
shown). Many of the previous studies tested serum folate, which we were not able to do 
because blood samples were obtained after diagnosis in cases. One of the objectives of this 
study was to investigate differences among the Whites and African Americans. 
Unfortunately, the small numbers of African Americans with MSI were small, which led to 
imprecise estimates as evidenced by the large 95% CIs. These insufficient data made it 
difficult to formulate any clear-cut conclusions. Additional weaknesses include missing 
genotype data due to refusals for blood draw and the need to combine several categories of 
data due to small numbers. We examined only two polymorphic loci, and according to Little 
et al. (46), >30 different polymorphic loci are related to folate metabolism, and by looking at 
only a few of these loci, we may be missing information on the role of other important loci.
In conclusion, we found that MTHFR variant genotypes were inversely associated with MSI 
when folate intake was adequate. This would imply that, under conditions of reduced 
MTHFR enzyme activity and abundant folate, a balance in folate pools is maintained for 
DNA methylation and DNA synthesis. In light of a lack of survival advantage for patients 
with MSI colon tumors undergoing treatment with 5-fluorouracil (47, 48) whose metabolism 
involves folate intermediates, our findings could have potential implications for colon 
cancer treatment and prevention. Our observations need to be confirmed in larger studies.
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Table 1
General characteristics of colon cancer cases and associations with MSI
MSS, n = 437 (%) MSI, n = 49 (%) OR (95% CI)
Age (median, 65 y)
 <65 212 (49) 17 (35) Reference
 ≥65 225 (51) 32 (65) 1.77 (0.96–3.290)
Gender
 Female 212 (49) 29 (59) Reference
 Male 225 (51) 20 (41) 0.65 (0.36–1.18)
Race
 Blacks 204 (47) 14 (29) Reference
 Whites 233 (53) 35 (71) 2.19 (1.14–4.18)
Family history
 No 350 (80) 35 (71) Reference
 Yes 87 (20) 14 (29) 1.61 (0.83–3.12)
Location of tumor
 Distal 165 (45) 8 (17) Reference
 Proximal 205 (55) 38 (83) 3.82 (1.74–8.42)
Stage of cancer at time of diagnosis
 Local 145 (39) 17 (39) Reference
 Regional 210 (59) 26 (59) 1.06 (0.55–2.02)
 Distant 41 (2) 1 (2) 0.21 (0.03–1.61)
Alcohol (category of use)
 None 306 (71) 27 (56) Reference
 Lower half 55 (13) 8 (17) 1.65 (0.71–3.82)
 Upper half 73 (17) 13 (27) 2.02 (0.99–4.10)
Smoking status
 Never 184 (42) 9 (19) Reference
 Former 184 (42) 26 (54) 2.89 (1.32–6.33)
 Current 67 (15) 13 (27) 3.97 (1.62–9.70)
NSAID use during past 5 y
 Never 48 (11) 10 (21) Reference
 Occasionally 177 (40) 23 (48) 0.62 (0.28–1.40)
 Frequently 212 (49) 15 (31) 0.34 (0.14–0.80)
Total calcium intake
 Quartile 1 113 (26) 7 (15) Reference
 Quartile 2 109 (25) 12 (25) 1.78 (0.68–4.68)
 Quartile 3 105 (24) 16 (33) 2.46 (0.97–6.22)
 Quartile 4 107 (25) 13 (27) 1.96 (0.75–5.10)
Vitamin/supplement use
 No/occasional 264 (61) 29 (62) Reference
 Regularly 166 (39) 18 (38) 0.99 (0.53–1.83)
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Table 2
Association between total, supplemental, and dietary folate and MSI
Variable Folate intake MSI, n (%) MSS, n (%) OR* (95% CI)
Total folate ≥400 17 (38) 128 (36) Reference
<400 28 (62) 232 (64) 1.06 (0.45–2.50)
Supplemental folate Yes 13 (29) 104 (29) Reference
No 32 (71) 256 (71) 0.98 (0.34–2.84)
Dietary folate ≥275 19 (42) 144 (40) Reference
<275 26 (58) 216 (60) 1.18 (0.6–2.50)
*
Adjusted for age, race, smoking status, total calcium intake, tumor location, and vitamin/mineral intake.
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